The major strength of our current study is that we have overcome the broad bactericidal effect of Dox by using a non-antimicrobial tetracycline analog (i.e., 9-TB) to induce NF-κB activation in CC10-CAIKKβ (NF-κB transgenic) mice. Here, NFKB1 is linked to tuberculosis.